Scynexis Inc (SCYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scynexis Inc (SCYX) has a cash flow conversion efficiency ratio of 0.373x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($18.40 Million) by net assets ($49.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SCYX net asset quality index to measure how much of total assets are equity-financed.
Scynexis Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Scynexis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Scynexis Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Scynexis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scynexis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daejoo Inc
KQ:003310
|
0.035x |
|
Excelsior Biopharma
TWO:6496
|
-0.028x |
|
Dancomech Holdings Bhd
KLSE:5276
|
0.019x |
|
Vection Technologies Ltd
AU:VR1
|
0.003x |
|
Aviation Links Ltd
TA:AVIA
|
0.028x |
|
Oricom Inc
KQ:010470
|
0.142x |
|
Singbao International Co Ltd
TWO:6130
|
-0.008x |
|
Mas Murni Indonesia Tbk
JK:MAMI
|
0.000x |
Annual Cash Flow Conversion Efficiency for Scynexis Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Scynexis Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see SCYX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $49.38 Million | $-5.28 Million | -0.107x | +75.46% |
| 2024-12-31 | $55.08 Million | $-24.01 Million | -0.436x | -152.87% |
| 2023-12-31 | $72.96 Million | $60.16 Million | 0.825x | +103.34% |
| 2022-12-31 | $3.23 Million | $-79.88 Million | -24.709x | -1768.45% |
| 2021-12-31 | $41.26 Million | $-54.56 Million | -1.322x | +39.02% |
| 2020-12-31 | $22.76 Million | $-49.35 Million | -2.169x | +26.64% |
| 2019-12-31 | $12.89 Million | $-38.12 Million | -2.956x | -225.90% |
| 2018-12-31 | $31.23 Million | $-28.32 Million | -0.907x | +20.91% |
| 2017-12-31 | $21.41 Million | $-24.56 Million | -1.147x | -36.05% |
| 2016-12-31 | $34.82 Million | $-29.35 Million | -0.843x | -44.08% |
| 2015-12-31 | $41.95 Million | $-24.55 Million | -0.585x | -106.51% |
| 2014-12-31 | $33.43 Million | $-9.47 Million | -0.283x | -157.23% |
| 2013-12-31 | $-8.70 Million | $-4.31 Million | 0.495x | -9.69% |
| 2012-12-31 | $-19.33 Million | $-10.60 Million | 0.548x | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory inva… Read more